VYNE THERAPEUTICS INC.

(VYNE)
  Report
Delayed Nasdaq  -  05/20 04:00:01 pm EDT
0.4001 USD   +0.15%
05/18VYNE Therapeutics to Present at HC Wainwright & Co. Global Investment Conference
AQ
05/17VYNE THERAPEUTICS INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
05/17TRANSCRIPT : VYNE Therapeutics Inc. - Special Call
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Valuation
Fiscal Period: December 2020 2021 2022 2023 2024
Capitalization1 26554,623,2--
Enterprise Value (EV)1 26554,623,223,223,2
P/E ratio -0,80x-0,72x-0,69x-0,49x-0,46x
Yield -----
Capitalization / Revenue 12,6x3,70x53,5x5,52x3,31x
EV / Revenue 12,6x3,70x53,5x5,52x3,31x
EV / EBITDA -----
Price to Book -----
Nbr of stocks (in thousands) 41 97053 51857 908--
Reference price (USD) 6,321,020,400,400,40
Announcement Date 03/04/202103/17/2022---
1 USD in Million
Estimates
Income Statement Evolution (Annual data)
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Net sales1 0,4421,014,80,434,207,00
EBITDA ------
Operating profit (EBIT)1 -95,9-253-68,0-41,9-45,8-48,7
Operating Margin -21 642%-1 203%-461%-9 664%-1 091%-696%
Pre-Tax Profit (EBT)1 -95,4-256-73,8-37,4-47,7-51,9
Net income1 -95,2-256-73,3-37,4-47,7-51,9
Net margin -21 485%-1 217%-497%-8 631%-1 136%-741%
EPS2 --7,88-1,42-0,58-0,82-0,88
Dividend per Share ------
Announcement Date 03/12/202003/04/202103/17/2022---
1 USD in Million
2 USD
Previous periodNext period
Estimates
Income Statement Evolution (Quarterly data)
Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4
Net sales1 4,092,290,180,100,100,10
EBITDA ------
Operating profit (EBIT)1 -17,8-12,0-8,69-9,77-11,5-12,9
Operating Margin -435%-525%-4 883%-9 767%-11 533%-12 933%
Pre-Tax Profit (EBT)1 -21,3-12,0-8,69-10,3-11,6-13,5
Net income1 -21,3-11,64,67-10,3-11,6-13,5
Net margin -521%-505%2 624%-10 300%-11 600%-13 500%
EPS2 -0,41-0,220,08-0,18-0,20-0,22
Dividend per Share ------
Announcement Date 11/10/202103/17/202205/12/2022---
1 USD in Million
2 USD
Previous periodNext period
Estimates
Balance Sheet Analysis
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Net Debt ------
Net Cash position ------
Leverage (Debt / EBITDA) ------
Free Cash Flow1 -74,5-137-56,4-49,7-55,9-63,8
ROE (Net Profit / Equities) ------
Shareholders' equity1 ------
ROA (Net Profit / Asset) ------
Assets1 ------
Book Value Per Share ------
Cash Flow per Share ------
Capex1 1,060,11-1,000,750,75
Capex / Sales 239%0,54%-231%17,9%10,7%
Announcement Date 03/12/202003/04/202103/17/2022---
1 USD in Million
Previous periodNext period
Estimates
Key data
Capitalization (USD) 23 169 186
Net sales (USD) 14 755 000
Number of employees 28
Sales / Employee (USD) 526 964
Free-Float 91,0%
Free-Float capitalization (USD) 21 093 521
Avg. Exchange 20 sessions (USD) 189 891
Average Daily Capital Traded 0,82%
EPS & Dividend